Team education · IDSA AMR Guidance v5.0

Resistant Enterobacterales: 25 questions

A self-scoring review of ESBL-producing, AmpC-producing, and carbapenem-resistant Enterobacterales, built from the IDSA 2026 guidance. Pick an answer and the rationale opens underneath, with the guidance question it comes from.

Source

IDSA 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections, version 5.0

Currency

Content current as of 1 March 2026; posted 30 July 2026; Clin Infect Dis 8 Aug 2026

Audience

APRNs, PAs, and physicians — weighted toward regimen selection over evidence grading

Part 1 of two. This set covers general management, ESBL-E, AmpC-E, and CRE urinary infection. Part 2 picks up from there: carbapenemase-directed therapy for invasive CRE, DTR Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia.